Venetoclax
| CAS No. | 1257044-40-8 | Cat. No. | BCP06811 |
| Name | Venetoclax | ||
| Synonyms | GDC-0199; ABT199; ABT199; GDC0199; GDC 0199;ABT-199; | ||
| Formula | C45H50ClN7O7S | M. Wt | 868.44 |
| Description | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process. Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma. | ||
| Pathways | Apoptosis Pathway | ||
| Targets | Bcl2 | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.